Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Clinical evaluation of a multi-parameter customized respiratory TaqMan® array card compared to conventional methods in immunocompromised patients

Deborah Steensels a,*, Marijke Reynders b, Patrick Descheemaeker b, Martin D. Curran c, Frédérique Jacobs d, Olivier Denis a, Marie-Luce Delforge a, Isabel Montesinos a

a Department of Clinical Microbiology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
b Department of Clinical Microbiology, AZ St-Jan Brugge-Oostende Hospital, Brugge, Belgium
c Public Health England, Clinical Microbiology and Public Health Laboratory, Addenbrooke’s Hospital, Cambridge, United Kingdom
d Department of Infectious Diseases, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium

ARTICLE INFO

Article history:
Received 2 July 2015
Received in revised form 26 August 2015
Accepted 31 August 2015

Keywords:
Respiratory virus infections
Multi-pathogen molecular assay
Conventional methods
Immunocompromised patients

ABSTRACT

Background: Respiratory viral infections can cause significant morbidity and mortality in immunocompromised patients. Conventional tests routinely available at most institutions are limited by the number of detectable pathogens, by a poor sensitivity and/or a long turnaround time.

Objectives: To compare the performance of routine conventional testing with direct fluorescent antibody assays and viral culture to a customized TaqMan® array card (TAC) real-time PCR method, targeting 24 viruses, 8 bacteria and 2 fungi simultaneously.

Study design: We collected 143 respiratory samples from 120 symptomatic immunocompromised patients. Samples for which conventional and TAC results were discordant underwent further verification testing.

Results: The TAC assay identified viral pathogens in more samples than did conventional testing (77/143 versus 27/143; McNemar P<0.0001), even when TAC results for viruses that could not be detected by conventional testing were excluded from analysis (59/143 versus 26/143; P<0.0001). In addition, the TAC assay identified 18 samples with non-viral pathogens. Verification testing confirmed positive TAC results for 50 out of 55 samples for which conventional testing was negative. Two out of three samples with a positive conventional test but negative TAC result were confirmed positive. A viral and a total pathogen co-infection rate of 5.6% and 11.8% were found, respectively.

Conclusions: The customized TAC assay resulted in a significantly increased identification of respiratory viruses. This study provides a practical real-life assessment of the performance of the TAC assay in a population for whom rapid and accurate diagnosis of viral and atypical pathogens is crucial for appropriate clinical management.

© 2015 Elsevier B.V. All rights reserved.

1. Background

Acute respiratory infections account for an estimated 75% of all acute morbidities in developed countries, and most of them (approximately 80%) have a viral etiology [1]. Viruses usually associated with self-limited upper respiratory tract illness in immunocompetent hosts, can evoke lower respiratory tract infections leading to bronchiolitis, pneumonitis/pneumonia or acute respiratory distress syndrome (ARDS) associated to a significant morbidity and mortality in immunocompromised hosts [2–6].

Until recently, the primary diagnostic tools for respiratory viruses included direct fluorescent antibody (DFA) assays, enzyme immunoassays, and viral culture. While DFA assays and enzyme immunoassays have a rapid turnaround time, sensitivity is limited, especially in adults. For cultivable viruses, viral culture is clearly more sensitive but it requires both several days of incubation, experienced lab technicians, and it is labor intensive. Molecular testing has greatly improved the laboratory’s ability to diagnose viral respiratory tract infections [1]. Multiplex PCR coupled with fluidic microarrays using microbeads or DNA chips (oligonucleotides spotted onto a slide or chips) represents the latest diagnostic approach...
for the clinical laboratory. Many commercial as well as in-house developed assays exist nowadays which offer a syndromic based approach for the detection of respiratory pathogens. This study focusses on the TaqMan® Array Card (TAC) (Thermo Fisher Scientific, Life Technologies, Carlsbad, CA), a microfluidic technology based on singleplex, reverse transcription real-time PCR in a 384-well microfluidic card. These cards are already commercialized for multiple gene expression and micro-RNA expression analyses and have been extensively used in cancer research [7–9]. For infectious diseases diagnostics, only in-house developed custom-made TAC assays exist to date [10–14].

2. Objectives

The goals of the present study are firstly to characterize the performance of a customized respiratory TAC assay (Patent number PCT/GB2012/053076; premarket version Cambridge-Brugge) on bronchoalveolar lavage (BAL) and nose-throat swab (NTS) samples in immunocompromised patients in comparison to standard conventional testing for the detection of respiratory viruses. Secondly, we aim to gain insight in the role of respiratory viruses, atypical bacteria and opportunistic fungi as etiologic agents of upper and lower respiratory tract infections in immunocompromised patients.

3. Study design

3.1. Patients and samples

The study population included 120 adult immunocompromised patients with symptoms of an upper or lower respiratory tract infection that underwent testing for respiratory pathogens at the University Hospital Erasme between December 2014 and April 2015. Immunocompromised status was defined as presence of a disease and/or treatment known to impair the immune system, such as solid organ transplant (SOT) under immunosuppressive therapy, solid or hematological malignancy under chemotherapy, or other underlying disease needing long-term corticosteroids therapy or immunosuppressive therapy. Patients infected with HIV with a CD4 count <200/mm³ were also included. Electronic medical records were reviewed retrospectively for clinical details using a structured case report form. After conventional testing, the samples were aliquoted and stored at –80°C until study testing.

3.2. Conventional testing

The following DFA respiratory virus tests were performed on all included BAL and NTS samples: influenza A (IA) and B (IB) viruses, adenovirus, respiratory syncytial virus (RSV) (Argene, Verniolle, France), parainfluenza viruses (PIV) 1–3 (Argene, Verniolle, France and Light Diagnostics, Millipore, USA) and human metapneumovirus (hMPV) (Light Diagnostics, Millipore, USA). For all samples, rapid viral culture (Shell vial LLC–MK2) for adenovirus, PIV1–3, RSV and influenza A/B was performed and additionally conventional viral culture on two supplementary cell lines (A549 and MRC-5) was realized for BAL samples.

3.3. Nucleic acid extraction

Nucleic acids were extracted from 800 μL input sample on the QiaSymphony (Qiagen, Valencia, CA) using the DSP viral pathogen midi kit in combination with the “Pathogen/Complex 800,V5_DSP” generic DNA-RNA extraction protocol and eluted in 130 μL. A dilution of Phocine Distemper Virus (PDV) was added during extraction as internal extraction and inhibition control.

3.4. TAC testing

Patient samples were retrospectively tested for respiratory pathogens with a customized TAC respiratory panel which included testing for pathogens showed in Fig. 1. For each patient sample, 78 μL of nucleic acid extract and 26 μL of TaqMan Fast Virus 1-step mastermix (Thermo Fisher Scientific, Life Technologies, Carlsbad, CA) were mixed and added to the TAC sample port. Reverse transcriptase real-time PCR was performed on the QuantStudio 7 (Thermo Fisher Scientific, Life Technologies, Carlsbad, CA) using following amplification protocol: 50°C for 5 min, 95°C for 20 s, and 40 cycles of 95°C-1°C for 1 s followed by 60°C for 20 s. The system reported a cycle threshold for each positive PCR assay. Whenever a clear exponential amplification curve was registered, even for one gene target, the result was considered positive for the specific pathogen. Based on the internal QC (PDV) data %CV of 9.5% was registered, indicating a highly reproducible method.

3.5. Verification PCR testing

Discordant conventional respiratory virus testing and TAC assay results were verified using real-time PCR assays. Verification testing was also performed for all non-viral pathogens detected by the TAC assay. The same nucleic acid extract was used for TAC and verification testing. Assay description, executive laboratory, target(s) and reference for each verification test are shown in Table S1 in the supplemental material.

3.6. Resolution of concordant and discordant results

Samples were considered to be positive for a specific respiratory pathogen if results from conventional testing were positive and matched the TAC results. Samples were considered to be negative if the conventional testing and TAC testing both yielded negative results. In cases where the conventional testing result and the TAC result were discordant, the result of the confirmatory testing was regarded as the final result.

3.7. Statistical analysis

Conventional testing and the TAC assay were compared using the exact two-sided McNemar’s test. The calculated sensitivity, specificity, cPPV and cNPV and their corresponding exact 95% binomial confidence intervals were calculated separately for conventional testing and TAC testing. All statistical analyses were performed using the MedCalc software (Mariakerke, Belgium).

4. Results

One hundred-forty three samples were obtained from 120 immunocompromised patients who underwent respiratory pathogen testing for symptoms of upper or lower respiratory tract infection. Patient and sample characteristics are shown in Tables 1 and 2, respectively. Conventional testing identified 27 samples (18.9%) with one pathogen each among 143 samples. The TAC assay identified 77 samples with one or more viral respiratory pathogens (53.8%). Detailed results are shown in Fig. 2 and in Table 3. Almost one fifth of all included samples were positive for IA virus. The positivity rate was higher for NTS samples (63.9%) than for BAL samples (45.7%), but the difference was not statistically significant. For NTS samples only, the viral distribution at genus level was as follows: IA (27.8%), CMV (8.3%), rhinovirus (6.5%), and RSV and Coronavirus (5.5%) the most frequently encountered, followed by IB and hMPV (3.7%). Adenovirus and parainfluenza viruses were detected in only a limited number of samples (≤3.0%). For BAL samples, less IA (14.3%), RSV and Coronavirus (2.8%) were found but
Fig. 1. TaqMan array card layout for one sample with composition of the respiratory pathogens included. These microfluidic cards contain 384 individual wells separated into eight loading ports with 48 wells each. For each sample, one internal positive control (IC) with Phocine Distemper Virus (PDV) and three human DNA/RNA controls are included. For several pathogens, more than one genetic target is included (indicated with #).

Fig. 2. Results for conventional testing with DFA and viral culture (A) and TAC testing (B), including the numbers of pathogens and percentages of the total.

more CMV (11.4%), rhinovirus (8.6%) and IB (5.7%). Human MPV, adenovirus and PIV were not detected in BAL samples. In addition to the viral pathogens, the TAC assay identified 13 samples with *P. jirovecii*, 2 samples with *Aspergillus* species and 1 sample each with *B. parapertussis*, *M. pneumoniae* and *L. pneumophila*. When viral and non-viral pathogens were considered, more than one pathogen was detected in 17 samples (11.9%). Table 4 shows the combinations of these pathogens and Ct-values identified by TAC. Those most frequently involved in co-infections were CMV (*n* = 8), *P. jirovecii* (*n* = 7), rhinovirus (*n* = 5) and influenza A virus (*n* = 5).

The TAC assay was significantly more likely to detect a respiratory virus compared to routine conventional testing with DFA and viral culture (McNemar *P* < 0.0001). When TAC assay results for viruses that could not be detected by conventional testing (coronavirus, rhinovirus, CMV in NTS samples) (*n* = 18) and conventional testing results for HSV (*n* = 1) that could not be detected by TAC testing were excluded from analysis, the difference in diagnostic performance of the TAC assay in comparison to conventional testing was still significant (*P* < 0.0001).

Among 58 samples on which the two techniques disagreed for viral pathogens, 55 were negative by conventional testing while positive for one or more viral pathogens by the TAC assay. Fifty of these were confirmed by verification testing. Conventional testing identified a pathogen in 3 while TAC assay was negative, of which
Table 1
Baseline characteristics of the 120 patients from whom respiratory samples were collected.

| Characteristic                                      | Value           |
|----------------------------------------------------|-----------------|
| Age, median (range), Yrs.                          | 58.5 (22.94)    |
| Gender, male, No. (%)                              | 64 (53.3)       |
| Underlying condition, No. (%)                      |                 |
| – Solid organ transplantation                       | 59 (49.2)       |
| – Solid malignancy                                 | 26 (21.7)       |
| – Hematological malignancy                         | 21 (17.5)       |
| – Other underlying disease needing long-term        | 12 (10.0)       |
| corticosteroids therapy or immunosuppressive therapy|                 |
| – HIV CD4 < 200/mm³                                 | 2 (1.7)         |

Type of solid organ transplant, No. (%)
- Lung                                               | 23 (19.2)       |
- Kidney                                             | 19 (15.8)       |
- Liver                                              | 7 (5.8)         |
- Heart                                              | 7 (5.8)         |
- Combined*                                          | 3 (2.5)         |

*Lung = kidney, lung + heart, kidney + liver

* Table 1

2 confirmed by verification PCR (Table 3). Based on these results, viral disease was considered to be present in 75 samples (52.4%) and absent in 68 samples (47.6%). The calculated sensitivity, specificity, cPPV and cNPV of the TAC assay and conventional testing to detect a respiratory viral infection are displayed in Table 5. The cPPV of conventional testing and TAC testing was not significantly different (P = 0.25), but the cNPV of the TAC assay (96.7%) was substantially greater than that of routine conventional testing (57.8%) (P < 0.0001).

Verification testing was also performed for non-viral pathogens detected by the TAC assay. Out of 13 samples positive for *P. jirovecii*, 11 were confirmed. Verification testing confirmed the positive

Table 2
Type of sample and clinical indications of the 143 respiratory samples.

| Type of sample                                      | No. (%) of samples (a) |
|-----------------------------------------------------|-------------------------|
| Nose-throat swab                                    | 108 (75)                |
| Bronchoalveolar lavage                              | 35 (25)                 |
| Clinical indication for test                         |                         |
| upper respiratory tract infection                    | 29 (24)                 |
| lower respiratory tract infection                    | 93 (76)                 |

(a) Samples obtained from 120 patients, of whom 22 patients with more than one sample:
- 20 patients with NTS and BAL for the same clinical indication.
- One patient with one NTS during first respiratory episode, 1 month later NTS and BAL during second respiratory episode.
- One patient with NTS and BAL for different respiratory episodes.

Table 3
Results from conventional, TAC and verification testing for samples with discordant results.

| No. of samples (a) | TAC result | verification result |
|--------------------|------------|---------------------|
| 2                  | negative   | Adenovirus          |
| 11                 | negative   | CMV                 |
| 1                  | negative   | CMV                 |
| 7                  | negative   | Coronavirus (b)     |
| 3                  | negative   | hMPV                |
| 15                 | negative   | Influenza A         |
| 1                  | negative   | Influenza A         |
| 3                  | negative   | Influenza (d)       |
| 1                  | negative   | Influenza A (e)     |
| 4                  | negative   | Influenza B         |
| 1                  | negative   | Influenza B (g)     |
| 9                  | negative   | Rhinovirus          |
| 1                  | negative   | Rhinovirus (h)      |
| 4                  | negative   | RSV                 |

(a) n = 64 (58 samples in total, 6 samples with more than one discordant result).
(b) Coronavirus OC43 (n = 2), Coronavirus 229E (n = 4), Coronavirus NL63 (n = 1).
(c) HSV1 targets not included in TAC assay.
(d) Two samples with only 1/6 and one sample with 3/6 targets for influenza A weakly positive (Ct-value > 30).
(e) Only viral culture positive, verification PCR very weakly positive (Ct-value > 36).
(f) False positive DFA.
(g) Only 1/2 targets weakly positive (Ct-value > 30).
(h) 2/2 Targets for rhinovirus weakly positive (Ct-value > 30).

Table 4
Combinations and Ct-value of viral and non-viral pathogens identified by TAC in 17 samples.

| No. | AV | CoV | IA | IB | hMPV | PIV3 | RV | RSV A | CMV | BP | MP | LP | PJ | AS |
|-----|----|-----|----|----|------|------|----|-------|-----|----|----|----|----|----|
| 1   | 32 |     | 23 | 22 | 38   | 30   | 30 | 30    | 33  | 32 | 30 | 20 | 27 | 37 |
| 3   | 29 |     | 30 | 35 | 31   | 31   | 31 | 34    |     |    |    |    |    |
| 4   | 24 |     | 35 | 35 | 31   | 31   | 31 | 34    |     |    |    |    |    |
| 5   | 23 |     | 24 | 31 | 23   | 23   | 23 | 34    |     |    |    |    |    |
| 6   | 22 |     | 32 |    | 32   | 32   | 32 | 34    |     |    |    |    |    |
| 9   | 21 |     |    |    | 32   | 32   | 32 | 34    |     |    |    |    |    |
| 10  | 20 |     |    |    | 32   | 32   | 32 | 34    |     |    |    |    |    |
| 11  | 32 |     |    |    | 32   | 32   | 32 | 34    |     |    |    |    |    |
| 12  | 31 |     |    |    | 32   | 32   | 32 | 34    |     |    |    |    |    |
| 13  | 30 |     |    |    | 32   | 32   | 32 | 34    |     |    |    |    |    |
| 14  | 29 |     |    |    | 32   | 32   | 32 | 34    |     |    |    |    |    |
| 15  | 28 |     |    |    | 32   | 32   | 32 | 34    |     |    |    |    |    |
| 16  | 27 |     |    |    | 32   | 32   | 32 | 34    |     |    |    |    |    |
| 17  | 26 |     |    |    | 32   | 32   | 32 | 34    |     |    |    |    |    |

AV, adenovirus; CoV, coronavirus; IA, influenza A virus; IB, influenza B virus; hMPV, human metapneumovirus; PIV3, parainfluenza virus 3; RV, rhinovirus, RSV A, respiratory syncytial virus A; CMV, cytomegalovirus; BP, Bordetella parapertussis; MP, Mycoplasma pneumoniae; LP, Legionella pneumophila; PJ, Pneumocystis jirovecii; AS, Aspergillus species.
(a) OC43.
(b) 229E.
*Median Ct-value for different targets.
Table 5  
Calculated performance characteristics for TAC and conventional testing.

|          | DFA + viral culture | TAC       | P value |
|----------|---------------------|-----------|---------|
| % cSens (95% CI) | 34.7 (24.1, 46.5) | 97.3 (90.7, 99.6) | <0.0001 |
| % cSpec (95% CI)  | 96.8 (92.1, 99.8) | 91.2 (81.8, 96.7) | 0.9703  |
| % cPPV (95% CI)   | 96.3 (81.0, 99.4) | 92.4 (84.2, 97.1) | 0.2485  |
| % cNPV (95% CI)   | 57.8 (48.2, 66.9) | 96.9 (89.1, 99.5) | <0.0001 |

cSens, calculated sensitivity; cSpec, calculated specificity; cPPV, calculated positive predictive value; cNPV, calculated negative predictive value; CI, confidence interval; DFA, direct fluorescent antibody assay; TAC, Taqman array card.

result for Aspergillus species (n = 2), M. pneumoniae (n = 1) and B. parapertussis (n = 1) but not the one for L. pneumophila.

Twenty-one patients had a NTS and BAL sample collected during the same episode of respiratory tract infection symptoms. For 9 patients, both NTS and BAL were negative. The same viral pathogen was found both in the NTS as in the BAL sample for 10 patients when applying TAC testing, compared to only 1 patient by conventional testing [19]. The TAC test was confirmed by conventional testing, and while positive in 3 samples, the median threshold was much higher than that for the same viruses detected by the TAC assay in other samples and confirmed by validation testing. This could suggest very small amounts of virus present in these samples, leading to false-negative verification testing, although a non-specific amplification cannot be excluded.

Approximately 1 h was needed for TAC testing with card setup and run times, excluding sample extraction. While the time to result was similar for DFA assays (approximately 3 h), the results for rapid viral culture were reported after 3 days of incubation, and conventional viral culture took up to 3 weeks.

Comparing the overall positivity rate (52.4%) and the epidemiology of respiratory viruses found in this study with data from the literature is difficult. Important differences could be partially explained by the patient population, specimen type and period of sample collection from December to April (during the flu epidemic in Belgium; almost one fifth of all included samples were positive for influenza A virus), but also by the wide array of viruses included in the TAC assay and by the fact that all samples were collected from symptomatic patients. The importance of the specimen type is highlighted in several studies. In BAL specimens a diagnostic yield ranging from 3.6% to 32.0% was reported [15–17]. Soccal et al. evaluated paired nasopharyngeal and BAL fluid specimens and observed an overall viral positivity rate of 29.3% in the upper respiratory tract specimens and 17.2% in the BAL samples (P < 0.001) [18]. This study included coupled NTS and BAL samples from 21 patients, and found a similar positivity rate for both sample types (52.4% and 57.1%, respectively). When all samples were considered, the positivity rate was higher for NTS samples (63.9%) than for BAL samples (45.7%), but the difference was not statistically significant.

Dual and even triple infections are routinely reported using multiplex PCR and have accounted for between 8 and 11% of positive specimens [19–21]. The present study found 5.6% of samples with more than one viral pathogen, and 11.5% of samples showed co-infections if all included pathogens were considered. The exact clinical interpretation of these multi-pathogen screening results is not always easy. When Ct-values are moderate or higher, especially for opportunistic pathogens like CMV, P. jirovecii and Aspergillus species, benign (and asymptomatic) colonization, or contamination should be suspected. Here, carriage of these opportunistic pathogens was likely in 10 out of 17 samples for which the TAC assay found more than one pathogen. Nevertheless, low viral loads do not exclude clinical disease due to the virus [22].

The TAC format has several advantages over other multi-pathogen molecular assays. The cards are completely custom-made which offers a great flexibility. The composition of the card can be chosen in relation to the patient population of interest. To note, the card used in this study did not include herpesviruses (HSV-1/2, VZV, HHV-6) besides CMV, which could be of possible interest for an immunocompromised patient population [23]. Another advantage is the spatial separation of the 48 reaction wells which allows assays to be easily changed without the need for extensive re-optimisation and validation of a highly parallel multiplex assay. This could aid in the rapid inclusion of novel or emerging pathogens [14]. In addition, the technology uses real-time PCR which generates a semi-quantitative Ct-value, in contrast to many commercial multi-pathogen assays which only offer qualitative results. This tool is decisive for an adequate and correct interpretation of results, particularly in case of co-infections. Moreover, the workflow is simple and easy and the cost per test is relatively low in comparison to most commercial multi-pathogen molecular assays.

However, the small reaction volume of 1 μL may affect sensitivity since the equivalent of the sample in the final reaction mixture per individual well is low. PCRs in the singleplex format are theoretically one log more sensitive than the same assays in the Array Card format [10,24]. Also, samples cannot be treated individually, so a high turnover is needed to assure an acceptable turn-around time.

The TAC card developed by Kodani et al. [10] and modified by Weinberg et al. [24] contained duplicate wells for the detection of one same genetic target for each pathogen (except for IA virus for which 3 targets were present in double). However, due to genome variability, single target testing might lead to false-negative results [25]. The card used in this study included more than one genetic target for several pathogens, which is not only interesting to limit false-negative results, but it can also help in the interpretation of the results.

There are some limitations to our study. In contrast to conventional testing, TAC and verification testing was performed retrospectively. Therefore, the quality of the samples could have deteriorated due to the freeze-thaw cycle before TAC and verification testing. This study was also limited by the lack of verification testing on all samples.

In summary, in comparison to routine conventional testing for respiratory viruses, the TAC assay detected more viral pathogens among samples obtained from an immunocompromised population. This study provides a practical real-life assessment of the performance of the custom TAC assay in a population for whom rapid and accurate diagnosis of viral pathogens is crucial for appropriate clinical management.

Funding

None to declare.
Competing interests

None to declare.

Ethical approval

This study was approved by the ethical committee of the Erasme hospital.

Acknowledgements

We thank the technicians of our virology and molecular microbiology laboratory for their technical assistance during this study. We thank Anne Vankeerberghen of OLV Hospital Aalst, Elke Wollants and Kurt Beuselinck of University Hospital Leuven and Oriane Soetens of University Hospital Brussels and their molecular microbiology teams for part of the verification PCR work.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.jcv.2015.08.022.

References

[1] J.B. Mahony, Detection of respiratory viruses by molecular methods, Clin. Microbiol. Rev. 21 (2008) 716–747.
[2] M. Becquart, The challenge of respiratory virus infections in hematopoietic stem cell transplant recipients, Br. J. Haematol. 143 (2008) 455–467.
[3] J.A. Englund, M. Becquart, J. Kuypers, W.G. Nichols, R.C. Hackman, R.A. Morrow, D.N. Fredricks, L. Corey, Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients, Ann. Intern. Med. 144 (2006) 344–349.
[4] J.A. Gutman, A.J. Peck, J. Kuypers, M. Becquart, Rhinovirus as a cause of fatal lower respiratory tract infection in adult stem cell transplantation patients: a report of two cases, Bone Marrow Transplant 40 (2007) 809–811.
[5] M.G. Ison, M.G. Michaels, RNA respiratory viral infections in solid organ transplant recipients, Am. J. Transplant 9 (Suppl. 4) (2009) S166–S172.
[6] M. Kamboj, M. Gerhin, C.H. Guang, C. Brennan, J. Stiles, S. Balashov, S. Park, T.E. Kiehn, D.S. Perlin, E.G. Pamer, K.A. Sepkowitz, Clinical characterization of human metapneumovirus infection among patients with cancer, J. Infect. 57 (2008) 464–471.
[7] A.B. Hui, W. Shi, P.C. Boutros, N. Miller, M. Pintilie, T. Fyles, D. McCready, D. Wong, K. Gerster, L. Waldron, J. Jurisica, L.Z. Penn, F.F. Liu, Robust global micro-RNA profiling with formalinfixed paraffin-embedded breast cancer tissues, Lab. Invest. 89 (2009) 597–606.
[8] B. Sánchez-Esquirdón, A. Sánchez-Aguilera, C. Montalbán, C. Martín, R. Martínez, J. González-Carrero, C. Poderos, C. Bellas, M.P. Fresco, C. Morante, M.J. Mestre, M. Mendez, F. Mazorra, E. Condé, A. Castañol, P. Sánchez-Godoy, J.F. Tomas, M.M. Morente, M.A. Pris, J.F. García, Spanish Hodgkin’s lymphoma study group. A TaqMan low-density array to predict outcome in advanced Hodgkin’s lymphoma using paraffin-embedded samples, Clin. Cancer Res. 15 (2009) 1367–1375.
[9] A. Steg, W. Wang, C. Blanquicett, J.M. Grunda, I.A. Eltoun, K. Wang, D.J. Buchsbaum, S.M. Vickers, S. Russo, R.B. Diasio, A.R. Frost, A.F. LoBuglio, W.E. Grizzle, M.R. Johnson, Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma, J. Mol. Diagn. 8 (2006) 76–83.
[10] M. Kodani, G. Yang, L.M. Conklin, T.C. Travis, C.G. Whitney, L.J. Anderson, S.J. Schrag, T.H. Taylor Jr, B.W. Beall, R.F. Breiman, D.R. Feinik, M.K. Njenga, L.W. Mayer, M.S. Oberste, M.L. Tondella, J.M. Winchell, S.L. Lindstrom, D.D. Erdman, R.S. Fiebig, Application of TaqMan low-density arrays for simultaneous detection of multiple respiratory pathogens, J. Clin. Microbiol. 49 (6) (2011) 2175.
[11] J. Liu, J. Gratz, C. Amour, G. Kibiki, S. Becker, L. Janaki, J.J. Verweij, M. Tanucci, S.U. Sobuz, R. Haqie, D.M. Havestick, E.R. Houp, A laboratory-developed TaqMan array card for simultaneous detection of 19 enteropathogens, J. Clin. Microbiol. 51 (2) (2013) 472–480.
[12] M.H. Díaz, J.L. Waller, R.A. Napoliello, M.S. Islam, R.J. Wolff, D.J. Burken, R.L. Holden, V. Sririnivasan, M. Arvay, L. McGee, M.S. Oberste, C.G. Whitney, S.J. Schrag, J.M. Winchell, S.K. Saha, Optimization of multiple pathogen detection using the TaqMan array card: application for a population-based study of neonatal infection, PLoS One 8 (6) (2013) e66183.
[13] M. Kodani, T. Mixson-Hayden, J. Drobeniuc, S. Kamili, Rapid and sensitive approach to simultaneous detection of genomes of hepatitis A, B, C, D and E viruses, J. Clin. Virol. 61 (2) (2014) 260–264.
[14] P.A. Rachwal, H.L. Rose, V. Cox, R.A. Lukaszewski, A.L. Murch, S.A. Weller, The potential of TaqMan array cards for detection of multiple biological agents by real-time PCR, PLoS One 7 (4) (2012) e35971, e35971.
[15] L. Ren, R. Gonzalez, Z. Wang, Z. Xiang, Y. Wang, H. Zhou, J. Li, Y. Xiao, Q. Yang, J. Zhang, L. Chen, W. Wang, Y. Li, T. Li, X. Meng, Y. Zhang, G. Vernet, G. Paranhos-Baccalá, J. Chen, Q. Jin, J. Wang, Prevalence of human respiratory viruses in adults with acute respiratory tract infections in Beijing, 2005–2007, Clin. Microbiol. Infect. 15 (12) (2009) 1146–1153.
[16] C. Minosse, M. Selleri, M.S. Zaniratti, G. Cappiello, R. Longo, E. Schifano, A. Spanb, N. Petrosillo, F.N. Lauria, V. Puro, M.R. Capobianchi, Frequency of detection of respiratory viruses in the lower respiratory tract of hospitalized adults, J. Clin. Virol. 42 (2) (2008) 215–220.
[17] D.L. Yu, P.O. Bridesvaux, J.D. Aubert, P.M. Soccal, L. Kaiser, Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies, Am. J. Transpl 11 (5) (2011) 1071–1078.
[18] P.M. Soccal, J.D. Aubert, P.O. Bridesvaux, J. Garbino, Y. Thomas, T. Rochat, T.S. Rochat, P. Meylan, C. Tapparel, L. Kaiser, Upper and lower respiratory tract viral infections and acute graft rejection in lung transplant recipients, Clin. Infect. Dis. 51 (2) (2010) 163–170.
[19] J.Y. Chung, T.H. Han, S.W. Kim, E.S. Hwang, Respiratory picornavirus infections in Korean children with lower respiratory tract infections, Scand. J. Infect. Dis. 39 (2007) 250–254.
[20] J.B. Mahony, S. Cheng, M. Smieja, A. Petrich, S. Buracard, J. Babwah, Estabilishing the epidemiology of respiratory virus infections using molecular technology, abstr. C-070. Abstr. 107th Annu. Meet. Am. Soc. Microbiol. American Society for Microbiology, Washington DC. 2007.
[21] A. Pianegeli, M. Gentile, M. Di, P. arco, P. Pagnotti, C. Sagnolari, S. Trombetti, L.L. Russo, V. Tromba, C. Moretti, F. Midulla, G. Antonelli, Detection and typing by molecular techniques of respiratory viruses in children hospitalized for acute respiratory infection in Rome, Italy, J. Med. Virol. 79 (2007) 163–168.
[22] D. Schnell, J. Legoff, E. Mariotte, A. Seguin, E. Canet, V. Lemiale, M. Darmon, B. Schlemmer, F. Simon, E. Azoulay, Molecular detection of respiratory viruses in immunocompromised ICU patients: incidence and meaning, Respir. Med. 106 (2012) 1184–1191.
[23] J.K. Sanghvi, A. Bullotta, S. Husain, C.R. Rinaldo, Clinical evaluation of multiplex real-time PCR panels for rapid detection of respiratory viral infections, J. Med. Virol. 84 (2012) 162–169.
[24] G.A. Weinberg, K.C. Schnabel, D.D. Erdman, M.M. Prill, M.K. Iwane, L.M. Shelley, B.L. Whitaker, P.G. Szilagyi, C.B. Hall, Field evaluation of TaqMan array card (TAC) for the simultaneous detection of multiple respiratory viruses in children with acute respiratory infection, J. Clin. Virol. 57 (3) (2013) 254–260.
[25] D. Steensels, A. Vankeerberghen, H. De Beenhouwer, Towards multi-target testing in molecular microbiology, Int. J. Microbiol. (2013) 12105.